Medical Advocates
Pegylated Interferon alfa-2b (PEG-INTRON)
   
HCV Journal Citations

General Reports                 Special Populations
Dose Ranging Studies
 Pharmacokinetics
 Viral Dynamics
 Diagnostics/Monitoring
 Adverse Events
 Efficacy
Liver Fibrosis
 Liver Transplantation
 HIV/HCV Indications
 Treatment Strategies
 Treatment Failure

  
Peg Inf Alfa-2b HCV Main Page Main New/Newsworthy Home Page

Last Update:  September 28, 2015

 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 

Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C.
 Bruix J, Poynard T, Colombo M, Schiff E,  et al
Gastroenterology. 2011 Mar 16
 Abstract

WEEK-IN-REVIEW FEATURED REPORT
Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question?'
 Toyoda H, Kumada T.
Expert Opin Pharmacother. 2009 Nov 6.
 Abstract

Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell Counts.
 Avidan NU, Goldstein D, Rozenberg L, et al
J Acquir Immune Defic Syndr. 2009 Sep 30.
 Abstract

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
 Hiramatsu N, Oze T, Yakushijin T, et alJ
Viral Hepat. 2009 Jun 22.
Abstract

Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype
1b hepatitis C patients.
 Tsuji K, Kawakami Y, Aimitsu S, Kohno H,  et al
Hepatol Res. 2009 Feb 25.
Abstract

Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C.
 Nomura H, Miyagi Y, Tanimoto H, Ishibashi H. 
J Viral Hepat. 2009 Feb 12
 Abstract
 
Falsely Low Hemoglobin A(1c) Levels in a Patient Receiving Ribavirin and Peginterferon alfa-2b for Hepatitis C.
 Gross BN, Cross LB, Foard JC, Wood YA. 
Pharmacotherapy. 2009 Jan;29(1):121-3.
 Abstract
 
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.
 Taylor MW, Tsukahara T, McClintick JN, et al  
J Transl Med. 2008 Nov 5;6(1):66.
Abstract
 
Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b.
 Shudo E, Ribeiro RM, Perelson AS.  
J Viral Hepat. 2008 May;15(5):379-82.
Abstract
 
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
 Kamal SM, El Kamary SS, Shardell MD, et al  
 Hepatology. 2007 Oct 17;
Abstract
 
PEG-Interferon Alfa-2b for Acute Hepatitis C: A Review.
 Palumbo E.
Mini Rev Med Chem. 2007 Aug;7(8):839-43
 Abstract
 
Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.
 Bruno R, Sacchi P, Scagnolari C. et al  
Aliment Pharmacol Ther. 2007 Aug 1;26(3):369-76.
 Abstract

FULL-TEXT ARTICLE
Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study.
 Cadranel JF, Boujenah JL, Bourliere M, et al
Gastroenterol Clin Biol. 2007 Feb;31(2):180-4.
Paper
Dose Ranging Studies
 
  A dose-ranging study of pegylated interferon alfa-2b and ribavirinin chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
 Glue P, Rouzier-Panis R, Raffanel C, et al.
 Hepatology 2000 Sep;32(3):647-53
 Abstract
Pharmacokinetics
 
 
Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection.
 Howell CD, Dowling TH, Paul MA, et al 
Clin Gastroenterol Hepatol. 2008 Apr 11
Abstract
 
Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.
 Gupta SK, Swan SK, Marbury T, et al 
Br J Clin Pharmacol. 2007 Jun 6;
 Abstract
 
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.
 Dahari H, Markatou M, Zeremski M, et al
J Hepatol. 2007 Feb 22;
 Abstract

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
 Tsubota A, Akuta N, Suzuki F, et al.
 Intervirology 2002;45(1):33-42
 Abstract

Viral Dynamics
 
 
Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.
 François C, Descamps V, Brochot E, et al
J Med Virol. 2010 Oct;82(10):1640-6
 Abstract

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
 Grasso A, Malfatti F, Leo PD, et al
J Hepatol. 2009 Jul 23.
 Abstract

A WEEK-IN-REVIEW-FEATURED REPORT
 Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin.
 Martinot-Peignoux M, Maylin S, Moucari R, et al
Antivir Ther. 2009;14(4):501-11.
 Abstract

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis c patients receiving peginterferon Alpha-2b plus ribavirin.
 Chu CJ, Lee SD, Hung TH, et al  
Aliment Pharmacol Ther. 2008 Aug 1
 Abstract
 
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
 Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. 
J Viral Hepat. 2007 Oct;14(10):72
 Abstract
 
Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data.
 Mimidis K, Papadopoulos VP, Elefsiniotis I, et al   
J Gastrointestin Liver Dis. 2006 Sep;15(3):213-9.
 Abstract

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
 Tsubota A, Akuta N, Suzuki F, et al.
 Intervirology 2002;45(1):33-42
 Abstract
   
  Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
 Buti M, Sanchez-Avila F, Lurie Y, et al.
Hepatology 2002 Apr;35(4):930-6
 Abstract
Diagnostics/Monitoring
 
  Abbott RealTime HCV and Roche COBAS AmpliPrep/COBAS TaqMan HCV assay in predicting of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
 Matsuura K, Tanaka Y, Hasegawa I, et al
J  Clin Microbiol. 2008 Dec 17
 Abstract
Drug/Drug Interactions
 
Methadone
 
  The Effect of Multiple Doses of Peginterferon alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy.
 Gupta SK, Sellers E, Somoza E, et al  
J Clin Pharmacol. 2007 May;47(5):604-12.
Abstract
Liver Fibrosis
 
 
Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C:a semi-quantitative analysis
Rao HY, Li J, Zhang LF, Chen HY, et al
Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):96-100.||
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
 Sarmento-Castro R, Horta A, Vasconcelos O, et al  
J Infect. 2006 Dec 26;
 Abstract
 
Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S, Lyden E.
Liver Int. 2006 Jun;26(5):529-35.
 Abstract

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
 Poynard T, McHutchison J, Manns M, et al.
Gastroenterology 2002 May;122(5):1303-13
 Abstract
 
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
 Crippin JS, McCashland T, Terrault N, et al.
 Liver Transpl 2002 Apr;8(4):350-5
 Abstract
Liver Transplantation
     
 Peg Interferon alfa-2b/Ribavirin
 
 
Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation.
 Ichikawa T, Nakao K, Miyaaki H, et al 
Hepatol Res. 2009 Jul 13
 Abstract

Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
 Fernandez I, Meneu JC, Colina F, et al 
Liver Transpl. 2006 Dec;12(12):1805-12.
 Abstract
 
Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
Dumortier J, Ducos E, Scoazec JY, et al   
J Viral Hepat. 2006 Aug;13(8):538-43.
 Abstract
 
Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin.
 Neumann U, Puhl G, Bahra M, et al
Transplantation. 2006 Jul 15;82(1):43-47.
 Abstract
 
Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
 Dumortier J, Ducos E, Scoazec JY, et al
 J Viral Hepat. 2006 Aug;13(8):538-43.
 Abstract
 
HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
 Moreno A, Barcena R, Garcia-Garzon S, et al
 J Hepatol. 2005 Nov;43(5):783-90
 Abstract

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver
transplantation.
 Mukherjee S, Rogge J, Weaver L, Schafer DF.et al 
Transplant Proc. 2003 Dec;35(8):3042-4.
Abstract
Treatment Strategies
     
 
Effect of Peginterferon alfa-2b and Ribavirin on Hepatocellular Carcinoma Prevention in Older Patients with Chronic Hepatitis C.
 Honda T, Ishigami M, Hayashi H, et al
J Gastroenterol Hepatol. 2014 Aug 5.
 Abstract

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
 Dogan UB, Atabay A, Akin MS, Yalaki S.
Eur J Gastroenterol Hepatol. 2013 Mar 20
 Abstract

Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C.
 Matsui K, Iwabuchi S, Shimizu H,  et al
Hepatol Res. 2010 Jun 8
 Abstract

Extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
 Nagaki M, Shimizu M, Sugihara JI, et al
Aliment Pharmacol Ther. 2009 May 26.
 Abstract

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon-alfa/Ribavirin Therapy.
 Poynard T, Colombo M, Bruix J, et al 
Gastroenterology. 2009 Jan 22
 Abstract
 
The Effect of Pegylated Interferon-{alpha}2b and Ribavirin on Posttraumatic Stress DisorderSymptoms.
 Dieperink E, Leskela J, Dieperink ME, et al  
Psychosomatics. 2008 May-Jun;49(3):225-9.
 Abstract
 
Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon alpha-2b and Ribavirin.
 Kawashima A, Tsukamoto I, Koyabu T, et al 
Lipids. 2008 Mar 5
Abstract

Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
 Diago M, Crespo J, Olveira A, et al  
Aliment Pharmacol Ther. 2007 Oct 15;26(8):1131-8.
Abstract
Treatment Failure
 
  Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection.
 Gammal RS, Spooner LM, Abraham GM.
Am J Health Syst Pharm. 2014 Feb 1;71(3):204-8. .
 Abstract

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b:
a randomized trial.
 Jensen DM, Marcellin P, Freilich B, et al
Ann Intern Med. 2009 Apr 21
 Abstract
Special Populations
     
African Americans
 
  Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection.
 Howell CD, Dowling TH, Paul MA, et al 
Clin Gastroenterol Hepatol. 2008 Apr 11
Abstract
 
Children
 
  Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
 El-Karaksy HM, Mogahed EA, El-Raziky MS, et al 
J Interferon Cytokine Res. 2015 Sep 25
 Abstract

Efficacy and Safety of Peginterferon-alpha2b and Ribavirin Combination Therapy in Children With Chronic Hepatitis C Infection.
 Jara P, Hierro L, de la Vega A, et al 
Pediatr Infect Dis J. 2008 Jan 2
 Abstract
 
Hispanics
 
  Outcomes of an underserved Hispanic population with chronic hepatitis C treated with pegylated-interferon and ribavirin in a government-sponsored clinic
 Iturrino J, Sánchez CJ, Ortiz A, Romero CJ,  et al
P R Health Sci J. 2011 Mar;30(1):9-13.81-5.
 Abstract

Hemodialysis Patients
  Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts.
 Tseng PL, Chen TC, Chien YS,  et al
J Kdney Dis. 2013 Jun 5.
Abstract

Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients
undergoing haemodialysis.
Amarapurkar DN, Patel ND, Kirpalani AL.
Trop Gastroenterol. 2007 Jan-Mar;28(1):16-8
Abstract
 
Women
 
  Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy.
 Nishimura T, Yamaguchi K, Hashimoto H, et a
 Hepatol Res. 2012 Apr 4
 Abstract

Peg Inf Alfa-2b  HCV Main Page Main New/Newsworthy Home Page

Peginterferon alfa-2b